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LETTER TO THE EDITOR
Cisplatin in breast cancer
Sir - We would like to respond to the review on the use of
cisplatin in patients with advanced breast cancer, by Drs
Smith and Talbot, stating that data on the use of cisplatin
doses between 50-75 mg m-2 as primary cytostatic treatment
in breast cancer are lacking.
We have treated eight postmenopausal patients with ad-
vanced or recurrent breast cancer with first line cisplatin
80 mg m2 i.v. Dl q 3 weeks. Two patients had an incurable
primary tumour, three had skin or lymphnode metastases,
two pulmonary and one patient lytic bone lesions. Two
patients, one with an incurable primary and one patient with
regional lymphnode metastases achieved a complete response,
and one patient with a mediastinal mass had a partial re-
sponse. Three patients were stable and two had progressive
disease. Of concern however was the toxicity of this 1 day
schedule. Two patients had to stop for deteriorating renal
function, two had WHO grade 4 thrombocytopenia and
needed thrombocyte transfusion, one patient died at home of
leucopenia related fever and three patients refused all further
cytostatic treatment, as a result from gastrointestinal toxicity:
grade 3-4 nausea and vomiting, which occurred in all eight
patients, despite high dose metoclopramide.
In view of this unexpectedly severe toxicity, we have ter-
minated this phase 2 study. We are not aware of other data
reporting the same exaggerated side effects specifically in
patients with breast cancer. The use of carboplatin may
prevent the renal and gastrointestinal problems, but this drug
appears to be less effective for this condition. Moreover, it
cannot be combined as easily with other conventional cyto-
statics in a triple combination. In our opinion, the toxicity
and need for clinical treatment does not outweigh the
moderate efficacy of cisplatin in advanced breast cancer.
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